Cargando…

Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciuoderis, Karl, Perez, Laura, Alvarez, Catalina, Usuga, Jaime, Carvajal, Leidi, Cardona, Andrés, Maya, Maria A., Cloherty, Gavin, Hernandez-Ortiz, Juan P., Osorio, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156422/
https://www.ncbi.nlm.nih.gov/pubmed/37138300
http://dx.doi.org/10.1186/s13256-023-03904-2
_version_ 1785036536994070528
author Ciuoderis, Karl
Perez, Laura
Alvarez, Catalina
Usuga, Jaime
Carvajal, Leidi
Cardona, Andrés
Maya, Maria A.
Cloherty, Gavin
Hernandez-Ortiz, Juan P.
Osorio, Jorge E.
author_facet Ciuoderis, Karl
Perez, Laura
Alvarez, Catalina
Usuga, Jaime
Carvajal, Leidi
Cardona, Andrés
Maya, Maria A.
Cloherty, Gavin
Hernandez-Ortiz, Juan P.
Osorio, Jorge E.
author_sort Ciuoderis, Karl
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infection. CASE PRESENTATION AND FINDINGS: A case of a triple-vaccinated (Pfizer) 37-year-old Hispanic American (Colombian) male who developed urticaria after Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 breakthrough infection is described. Virus isolation and whole genome sequencing along with immune and molecular assays were performed. Dermatological manifestations (skin rash and urticaria) after Omicron BA.5.1 infection were observed. Sequence analysis of the Omicron BA.5.1 isolate also revealed several important mutations. Hemogram analysis revealed leukocytosis and neutrophilia. Serology testing revealed anti-spike immunoglobulin G serum titers but negative detection of immunoglobulin M at 10 days after symptom onset. Anti-nucleocapsid, anti-spike 1 immunoglobulin G, anti-spike trimer, and anti-receptor-binding-domain immunoglobulin G and immunoglobulin E sera were detected at different titers 10 days after symptom onset. Several serum levels of chemokines/cytokines (Interferon-α, interferon-γ, interleukin-12/interleukin-23p40, interleukin-18, interferon gamma-induced protein-10, monocyte chemoattractant protein-1, monokine induced by gamma, macrophage inflammatory protein-1α, chemokine (C-C motif) ligand-5 , tumor necrosis factor-β1, Tumor necrosis factor-α) were detected, but interleukin-2, interleukin-4, interleukin-6, interleukin-8, and interleukin-17A were below the limit of detection. INTERPRETATION AND CONCLUSIONS: To our knowledge, this is the first study describing skin effects of a severe acute respiratory syndrome coronavirus 2 Omicron BA.5 variant breakthrough infection in a triple-vaccinated patient in Colombia. Several important mutations were found in the spike glycoprotein of the virus isolated; these mutations are associated with immune evasion and changes in antigenic properties of the virus. Physicians overseeing coronavirus disease 2019 cases should be aware of the potential skin effects of the infection. Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection and its association with proinflammatory cytokines and chemokines may enhance the development of urticaria and other skin manifestations in immunized individuals. However, further studies are needed to better understand the complexity of coronavirus disease in such situations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13256-023-03904-2.
format Online
Article
Text
id pubmed-10156422
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101564222023-05-05 Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report Ciuoderis, Karl Perez, Laura Alvarez, Catalina Usuga, Jaime Carvajal, Leidi Cardona, Andrés Maya, Maria A. Cloherty, Gavin Hernandez-Ortiz, Juan P. Osorio, Jorge E. J Med Case Rep Case Report BACKGROUND: Severe acute respiratory syndrome coronavirus 2 continues to threaten public health. The virus is causing breakthrough infections in vaccinated individuals. Also, scarce information is available about cutaneous manifestations after severe acute respiratory syndrome coronavirus 2 infection. CASE PRESENTATION AND FINDINGS: A case of a triple-vaccinated (Pfizer) 37-year-old Hispanic American (Colombian) male who developed urticaria after Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 breakthrough infection is described. Virus isolation and whole genome sequencing along with immune and molecular assays were performed. Dermatological manifestations (skin rash and urticaria) after Omicron BA.5.1 infection were observed. Sequence analysis of the Omicron BA.5.1 isolate also revealed several important mutations. Hemogram analysis revealed leukocytosis and neutrophilia. Serology testing revealed anti-spike immunoglobulin G serum titers but negative detection of immunoglobulin M at 10 days after symptom onset. Anti-nucleocapsid, anti-spike 1 immunoglobulin G, anti-spike trimer, and anti-receptor-binding-domain immunoglobulin G and immunoglobulin E sera were detected at different titers 10 days after symptom onset. Several serum levels of chemokines/cytokines (Interferon-α, interferon-γ, interleukin-12/interleukin-23p40, interleukin-18, interferon gamma-induced protein-10, monocyte chemoattractant protein-1, monokine induced by gamma, macrophage inflammatory protein-1α, chemokine (C-C motif) ligand-5 , tumor necrosis factor-β1, Tumor necrosis factor-α) were detected, but interleukin-2, interleukin-4, interleukin-6, interleukin-8, and interleukin-17A were below the limit of detection. INTERPRETATION AND CONCLUSIONS: To our knowledge, this is the first study describing skin effects of a severe acute respiratory syndrome coronavirus 2 Omicron BA.5 variant breakthrough infection in a triple-vaccinated patient in Colombia. Several important mutations were found in the spike glycoprotein of the virus isolated; these mutations are associated with immune evasion and changes in antigenic properties of the virus. Physicians overseeing coronavirus disease 2019 cases should be aware of the potential skin effects of the infection. Pathogenesis of severe acute respiratory syndrome coronavirus 2 infection and its association with proinflammatory cytokines and chemokines may enhance the development of urticaria and other skin manifestations in immunized individuals. However, further studies are needed to better understand the complexity of coronavirus disease in such situations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13256-023-03904-2. BioMed Central 2023-05-04 /pmc/articles/PMC10156422/ /pubmed/37138300 http://dx.doi.org/10.1186/s13256-023-03904-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Ciuoderis, Karl
Perez, Laura
Alvarez, Catalina
Usuga, Jaime
Carvajal, Leidi
Cardona, Andrés
Maya, Maria A.
Cloherty, Gavin
Hernandez-Ortiz, Juan P.
Osorio, Jorge E.
Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title_full Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title_fullStr Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title_full_unstemmed Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title_short Urticaria after breakthrough Omicron BA.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (Pfizer) patient: a case report
title_sort urticaria after breakthrough omicron ba.5.1 severe acute respiratory syndrome coronavirus 2 infection in a triple-vaccinated (pfizer) patient: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156422/
https://www.ncbi.nlm.nih.gov/pubmed/37138300
http://dx.doi.org/10.1186/s13256-023-03904-2
work_keys_str_mv AT ciuoderiskarl urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT perezlaura urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT alvarezcatalina urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT usugajaime urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT carvajalleidi urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT cardonaandres urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT mayamariaa urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT clohertygavin urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT hernandezortizjuanp urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport
AT osoriojorgee urticariaafterbreakthroughomicronba51severeacuterespiratorysyndromecoronavirus2infectioninatriplevaccinatedpfizerpatientacasereport